How do you communicate the benefit of the newly approved combination of venetoclax plus azacitadine in the front line AML setting based on early phase clinical trial data compared to the historical standard of azacitadine monotherapy for patients who are not high dose chemotherapy induction candidates?
What would make one choose this combination over the also recently approved combination of glasdigib + lodac which was based off a randomized phase 2 study?